Sarepta (SRPT) volatility low into shares could have 'considerably more upside,' Barron's says

September 26, 2016 6:47 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Sarepta (SRPT) share price recently doubled after a surprise FDA approval of its Duchenne muscular dystrophy drug Exondys 51, Sarepta could have "considerably more upside" when taking into account traditional biotech valuation metrics, Barron's says. Option implied volatility index mean is at 59, compared to its 52-week range of 67 to 399, according to Livevol.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment